Effect of bisphosphonates and statins on the in vitro radiosensitivity of breast cancer cell lines.
Bisphosphonates
Breast cancer
DNA repair
Radiosensitivity
Statins
Journal
Pharmacological reports : PR
ISSN: 2299-5684
Titre abrégé: Pharmacol Rep
Pays: Switzerland
ID NLM: 101234999
Informations de publication
Date de publication:
27 Dec 2023
27 Dec 2023
Historique:
received:
14
07
2023
accepted:
20
11
2023
revised:
17
11
2023
medline:
28
12
2023
pubmed:
28
12
2023
entrez:
27
12
2023
Statut:
aheadofprint
Résumé
Early-stage breast cancer is usually treated with breast-conserving surgery followed by adjuvant radiation therapy. Acute skin toxicity is a common radiation-induced side effect experienced by many patients. Recently, a combination of bisphosphonates (zoledronic acid) and statins (pravastatin), or ZOPRA, was shown to radio-protect normal tissues by enhancing DNA double-strand breaks (DSB) repair mechanism. However, there are no studies assessing the effect of ZOPRA on cancerous cells. The purpose of this study is to characterize the in vitro effect of the zoledronic acid (ZO), pravastatin (PRA), and ZOPRA treatment on the molecular and cellular radiosensitivity of breast cancer cell lines. Two breast cancer cell lines, MDA MB 231 and MCF-7, were tested. Cells were treated with different concentrations of pravastatin (PRA), zoledronate (ZO), as well as their ZOPRA combination, before irradiation. Anti-γH2AX and anti-pATM immunofluorescence were performed to study DNA DSB repair kinetics. MTT assay was performed to assess cell proliferation and viability, and flow cytometry was performed to analyze the effect of the drugs on the cell cycle distribution. The clonogenic assay was used to assess cell survival. ZO, PRA, and ZOPRA treatments were shown to increase the residual number of γH2AX foci for both cell lines. ZOPRA treatment was also shown to reduce the activity of the ATM kinase in MCF-7. ZOPRA induced a significant decrease in cell survival for both cell lines. Our findings show that pretreatment with ZOPRA can decrease the radioresistance of breast cancer cells at the molecular and cellular levels. The fact that ZOPRA was previously shown to radioprotect normal tissues, makes it a good candidate to become a therapeutic window-widening drug.
Sections du résumé
BACKGROUND
BACKGROUND
Early-stage breast cancer is usually treated with breast-conserving surgery followed by adjuvant radiation therapy. Acute skin toxicity is a common radiation-induced side effect experienced by many patients. Recently, a combination of bisphosphonates (zoledronic acid) and statins (pravastatin), or ZOPRA, was shown to radio-protect normal tissues by enhancing DNA double-strand breaks (DSB) repair mechanism. However, there are no studies assessing the effect of ZOPRA on cancerous cells. The purpose of this study is to characterize the in vitro effect of the zoledronic acid (ZO), pravastatin (PRA), and ZOPRA treatment on the molecular and cellular radiosensitivity of breast cancer cell lines.
MATERIALS
METHODS
Two breast cancer cell lines, MDA MB 231 and MCF-7, were tested. Cells were treated with different concentrations of pravastatin (PRA), zoledronate (ZO), as well as their ZOPRA combination, before irradiation. Anti-γH2AX and anti-pATM immunofluorescence were performed to study DNA DSB repair kinetics. MTT assay was performed to assess cell proliferation and viability, and flow cytometry was performed to analyze the effect of the drugs on the cell cycle distribution. The clonogenic assay was used to assess cell survival.
RESULTS
RESULTS
ZO, PRA, and ZOPRA treatments were shown to increase the residual number of γH2AX foci for both cell lines. ZOPRA treatment was also shown to reduce the activity of the ATM kinase in MCF-7. ZOPRA induced a significant decrease in cell survival for both cell lines.
CONCLUSIONS
CONCLUSIONS
Our findings show that pretreatment with ZOPRA can decrease the radioresistance of breast cancer cells at the molecular and cellular levels. The fact that ZOPRA was previously shown to radioprotect normal tissues, makes it a good candidate to become a therapeutic window-widening drug.
Identifiants
pubmed: 38151641
doi: 10.1007/s43440-023-00560-7
pii: 10.1007/s43440-023-00560-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Faculty of Medicine, American University of Beirut
ID : 104262
Informations de copyright
© 2023. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.
Références
Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.
pubmed: 12393820
doi: 10.1056/NEJMoa022152
Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–32.
pubmed: 12393819
doi: 10.1056/NEJMoa020989
Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.
pubmed: 22019144
doi: 10.1016/S0140-6736(11)61629-2
Bray FN, Simmons BJ, Wolfson AH, Nouri K. Acute and chronic cutaneous reactions to ionizing radiation therapy. Dermatol Ther (Heidelb). 2016;6(2):185–206.
pubmed: 27250839
doi: 10.1007/s13555-016-0120-y
Singh M, Alavi A, Wong R, Akita S. Radiodermatitis: a review of our current understanding. Am J Clin Dermatol. 2016;17(3):277–92.
pubmed: 27021652
doi: 10.1007/s40257-016-0186-4
Leventhal J, Young MR. Radiation dermatitis: recognition, prevention, and management. Oncology. 2017;31(12):885–7.
pubmed: 29297172
Bodgi L, Granzotto A, Devic C, Vogin G, Lesne A, Bottollier-Depois JF, et al. A single formula to describe radiation-induced protein relocalization: towards a mathematical definition of individual radiosensitivity. J Theor Biol. 2013;333:135–45.
pubmed: 23735818
doi: 10.1016/j.jtbi.2013.05.020
Le Reun E, Bodgi L, Granzotto A, Sonzogni L, Ferlazzo ML, Al-Choboq J, et al. Quantitative correlations between radiosensitivity biomarkers show that the ATM protein kinase is strongly involved in the radiotoxicities observed after radiotherapy. Int J Mol Sci. 2022;23(18):10434.
pubmed: 36142346
pmcid: 9498991
doi: 10.3390/ijms231810434
Goutham HV, Mumbrekar KD, Vadhiraja BM, Fernandes DJ, Sharan K, Kanive Parashiva G, et al. DNA double-strand break analysis by gamma-H2AX foci: a useful method for determining the overreactors to radiation-induced acute reactions among head-and-neck cancer patients. Int J Radiat Oncol Biol Phys. 2012;84(5):e607–12.
pubmed: 22836053
doi: 10.1016/j.ijrobp.2012.06.041
Rothkamm K, Lobrich M. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proc Natl Acad Sci U S A. 2003;100(9):5057–62.
pubmed: 12679524
pmcid: 154297
doi: 10.1073/pnas.0830918100
Bodgi L, Foray N. The nucleo-shuttling of the ATM protein as a basis for a novel theory of radiation response: resolution of the linear-quadratic model. Int J Radiat Biol. 2016;92(3):117–31.
pubmed: 26907628
doi: 10.3109/09553002.2016.1135260
Granzotto A, Benadjaoud MA, Vogin G, Devic C, Ferlazzo ML, Bodgi L, et al. Influence of nucleoshuttling of the ATM protein in the healthy tissues response to radiation therapy: toward a molecular classification of human radiosensitivity. Int J Radiat Oncol Biol Phys. 2016;94(3):450–60.
pubmed: 26867874
doi: 10.1016/j.ijrobp.2015.11.013
Maalouf M, Granzotto A, Devic C, Bodgi L, Ferlazzo M, Peaucelle C, et al. Influence of linear energy transfer on the nucleo-shuttling of the ATM protein: a novel biological interpretation relevant for particles and radiation. Int J Radiat Oncol Biol Phys. 2019;103(3):709–18.
pubmed: 30342967
doi: 10.1016/j.ijrobp.2018.10.011
Colin C, Devic C, Noël A, Rabilloud M, Zabot M-T, Pinet-Isaac S, et al. DNA double-strand breaks induced by mammographic screening procedures in human mammary epithelial cells. Int J Radiat Biol. 2011;87(11):1103–12.
pubmed: 21797809
doi: 10.3109/09553002.2011.608410
Wang H, Mu X, He H, Zhang X-D. Cancer radiosensitizers. Trends Pharmacol Sci. 2018;39(1):24–48.
pubmed: 29224916
doi: 10.1016/j.tips.2017.11.003
Ferlazzo ML, Sonzogni L, Granzotto A, Bodgi L, Lartin O, Devic C, et al. Mutations of the Huntington’s disease protein impact on the ATM-dependent signaling and repair pathways of the radiation-induced DNA double-strand breaks: corrective effect of statins and bisphosphonates. Mol Neurobiol. 2014;49:1200–11.
pubmed: 24277524
doi: 10.1007/s12035-013-8591-7
Ferlazzo ML, Bach-Tobdji MKE, Djerad A, Sonzogni L, Devic C, Granzotto A, et al. Radiobiological characterization of tuberous sclerosis: a delay in the nucleo-shuttling of ATM may be responsible for radiosensitivity. Mol Neurobiol. 2018;55(6):4973–83.
pubmed: 28786016
doi: 10.1007/s12035-017-0648-6
Combemale P, Sonzogni L, Devic C, Bencokova Z, Ferlazzo ML, Granzotto A, et al. Individual response to radiation of individuals with neurofibromatosis Type I: Role of the ATM protein and influence of statins and bisphosphonates. Mol Neurobiol. 2022;59(1):556–73.
pubmed: 34727321
doi: 10.1007/s12035-021-02615-3
Al-Choboq J, Ferlazzo ML, Sonzogni L, Granzotto A, El-Nachef L, Maalouf M, et al. Usher syndrome belongs to the genetic diseases associated with radiosensitivity: influence of the ATM protein kinase. Int J Mol Sci. 2022;23(3):1570.
pubmed: 35163494
pmcid: 8836140
doi: 10.3390/ijms23031570
Moulay Lakhdar I, Ferlazzo ML, Al Choboq J, Berthel E, Sonzogni L, Devic C, et al. Fibroblasts from retinoblastoma patients show radiosensitivity linked to abnormal localization of the ATM protein. Curr Eye Res. 2021;46(4):546–57.
pubmed: 32862699
doi: 10.1080/02713683.2020.1808998
Francis M, Ahmad A, Bodgi L, Azzam P, Youssef T, Abou Daher A, et al. SMPDL3b modulates radiation-induced DNA damage response in renal podocytes. FASEB J. 2022;36(10): e22545.
pubmed: 36094323
doi: 10.1096/fj.202100186RR
Early Breast Cancer Trialists' Collaborative G. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386(10001):1353–1361.
Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey SG, et al. (2013) Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:4816.
Korte V, Gademann G, Gawish A, Ochel H-J. Modulation of radiosensitivity of DU145 prostate carcinoma cells by simvastatin. J Cancer Res Clin Oncol. 2023;149(8):4509–14.
pubmed: 36127484
doi: 10.1007/s00432-022-04364-9
d’Hose D, Mignion L, Hamelin L, Sonveaux P, Jordan BF, Gallez B. Statins alleviate tumor hypoxia in prostate cancer models by decreasing oxygen consumption: an opportunity for radiosensitization? Biomolecules. 2022;12(10):1418.
pubmed: 36291627
pmcid: 9599109
doi: 10.3390/biom12101418
Nowakowska MK, Lei X, Thompson MT, Shaitelman SF, Wehner MR, Woodward WA, et al. Association of statin use with clinical outcomes in patients with triple-negative breast cancer. Cancer. 2021;127(22):4142–50.
pubmed: 34342892
doi: 10.1002/cncr.33797
Zhao G, Ji Y, Ye Q, Ye X, Wo G, Chen X, et al. Effect of statins use on risk and prognosis of breast cancer: a meta-analysis. Anticancer Drugs. 2022;33(1):e507–18.
pubmed: 34407042
doi: 10.1097/CAD.0000000000001151
Varela I, Pereira S, Ugalde AP, Navarro CL, Suarez MF, Cau P, et al. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med. 2008;14(7):767–72.
pubmed: 18587406
doi: 10.1038/nm1786
Rahal OM, Woodward WA. Cholesterol and radiosensitivity. Curr Breast Cancer Rep. 2016;8(1):32–9.
doi: 10.1007/s12609-016-0202-y
Misra J, Mohanty ST, Madan S, Fernandes JA, Ebetino FH, Russell RGG, et al. Zoledronate attenuates accumulation of DNA damage in mesenchymal stem cells and protects their function. Stem Cells. 2016;34(3):756–67.
pubmed: 26679354
doi: 10.1002/stem.2255
Soto DE, Daignault S, Sandler HM, Ray ME. No Effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology. 2009;73(1):158–62.
pubmed: 18722651
doi: 10.1016/j.urology.2008.02.055
Kim EH, Kim M-S, Lee K-H, Koh J-S, Jung W-G, Kong C-B. Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma. Oncotarget. 2016;7(43):70869–80.
pubmed: 27765919
pmcid: 5342595
doi: 10.18632/oncotarget.12281
Alcaraz M, Olivares A, Achel DG, Alcaraz-Saura M. Effects of bisphosphonates in combination with ionizing radiation and antioxidants on the growth of prostate and melanoma cells lines. Anticancer Res. 2013;33(8):3217–24.
pubmed: 23898082
Kars MD, Iseri ÖD, Ural AU, Avcu F, Beyzadeoglu M, Dirican B, et al. Development of radioresistance in drug resistant human MCF-7 breast cancer cells. J Radiother Pract. 2009;8(4):207–13.
doi: 10.1017/S1460396909990070
Collection ATC. MCF7 (ATCC® HTB-22™) ATCC; [Available from: https://www.atcc.org/products/all/htb-22.aspx#generalinformation
Collection ATC. MDA-MB-231 (ATCC® HTB-26™) [Available from: https://www.atcc.org/products/all/htb-26.aspx#
Njeh CF, Salmon HW, Schiller C. The impact of dose rate on the accuracy of step-and-shoot intensity-modulated radiation therapy quality assurance using varian 2300CD. J Med Phys. 2017;42(4):206–12.
pubmed: 29296034
pmcid: 5744448
doi: 10.4103/jmp.JMP_18_17
Valentin J. Relative biological effectiveness (RBE), quality factor (Q), and radiation weighting factor (wR):ICRP Publication 92: Approved by the Commission in January 2003. Ann ICRP. 2003;33(4):1–121.
doi: 10.1016/S0146-6453(03)00024-1
Liston DR, Davis M. Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies. Clin Cancer Res. 2017;23(14):3489.
pubmed: 28364015
pmcid: 5511563
doi: 10.1158/1078-0432.CCR-16-3083
Puck TT, Marcus PI. Action of x-rays on mammalian cells. J Exp Med. 1956;103(5):653–66.
pubmed: 13319584
pmcid: 2136626
doi: 10.1084/jem.103.5.653
Bodgi L, Bahmad HF, Araji T, Al Choboq J, Bou-Gharios J, Cheaito K, et al. Assessing radiosensitivity of bladder cancer in vitro: A 2D vs. 3D approach. Front Oncol. 2019. https://doi.org/10.3389/fonc.2019.00153 .
doi: 10.3389/fonc.2019.00153
pubmed: 30941305
pmcid: 6433750
Rothkamm K, Kruger I, Thompson LH, Lobrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol. 2003;23(16):5706–15.
pubmed: 12897142
pmcid: 166351
doi: 10.1128/MCB.23.16.5706-5715.2003
Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273(10):5858–68.
pubmed: 9488723
doi: 10.1074/jbc.273.10.5858
Grote SJ, Joshi GP, Revell SH, Shaw CA. Observations of radiation-induced chromosome fragment loss in live mammalian cells in culture, and its effect on colony-forming ability. Int J Radiat Biol Relat Stud Phys Chem Med. 1981;39(4):395–408.
pubmed: 6971848
doi: 10.1080/09553008114550491
Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421(6922):499–506.
pubmed: 12556884
doi: 10.1038/nature01368
Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem. 2001;276(45):42462–7.
pubmed: 11571274
doi: 10.1074/jbc.C100466200
Wasserman TH, Twentyman P. Use of a colorimetric microtiter (MTT) assay in determining the radiosensitivity of cells from murine solid tumors. Int J Radiat Oncol Biol Phys. 1988;15(3):699–702.
pubmed: 3417490
doi: 10.1016/0360-3016(88)90314-8
Slavotinek A, McMillan TJ, Steel CM. Measurement of radiation survival using the MTT assay. Eur J Cancer. 1994;30(9):1376–82.
doi: 10.1016/0959-8049(94)90189-9
Foray N, Bourguignon M, Hamada N. Individual response to ionizing radiation. Mutat Res. 2016;770(Pt B):369–86.
doi: 10.1016/j.mrrev.2016.09.001
Jiang H, Panda S, Gekara NO. Comet and micronucleus assays for analyzing DNA damage and genome integrity. Methods Enzymol. 2019;625:299–307.
pubmed: 31455533
doi: 10.1016/bs.mie.2019.05.015
ICRP. Prevention of accidental exposures to patients undergoing radiation therapy. A report of the International Commission on Radiological Protection. 2000. Report No.: 0146–6453 Contract No.: 3.
Elzahhar PA, Nematalla HA, Al-Koussa H, Abrahamian C, El-Yazbi AF, Bodgi L, et al. Inclusion of Nitrofurantoin into the Realm of Cancer Chemotherapy via Biology-Oriented Synthesis and Drug Repurposing. J Med Chem. 2023;66:4565–87.
pubmed: 36921275
doi: 10.1021/acs.jmedchem.2c01408
Lesueur P, Chevalier F, Austry J-B, Waissi W, Burckel H, Noël G, et al. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget. 2017;8(40):69105–24.
pubmed: 28978184
pmcid: 5620324
doi: 10.18632/oncotarget.19079
Ortiz T, Burguillos MA, López-Lluch G, Navas P, Herrador M, González I, et al. Enhanced induction of apoptosis in a radio-resistant bladder tumor cell line by combined treatments with X-rays and wortmannin. Radiat Environ Biophys. 2008;47(4):445–52.
pubmed: 18787832
doi: 10.1007/s00411-008-0188-6
Brichkina A, Bulavin DV. Cancer suppression by systemic inactivation of p38MAPK. Oncotarget. 2017;8(9):14275–6.
pubmed: 28199960
pmcid: 5362401
doi: 10.18632/oncotarget.15293
Tu X, Kahila MM, Zhou Q, Yu J, Kalari KR, Wang L, et al. ATR inhibition is a promising radiosensitizing strategy for triple-negative breast cancer. Mol Cancer Ther. 2018;17(11):2462.
pubmed: 30166399
pmcid: 6215494
doi: 10.1158/1535-7163.MCT-18-0470
Overgaard J, Horsman MR. Modification of hypoxia induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol. 1996;6:10–21.
pubmed: 10717158
doi: 10.1016/S1053-4296(96)80032-4
Azzi J, Waked A, Bou-Gharios J, Al Choboq J, Geara F, Bodgi L, et al. Radiosensitizing effect of curcumin on human bladder cancer cell lines: impact on DNA repair mechanisms. Nutr Cancer. 2022;74(6):2207–21.
pubmed: 34643466
doi: 10.1080/01635581.2021.1985534
Hatanaka T. Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet. 2000;39(6):397–412.
pubmed: 11192473
doi: 10.2165/00003088-200039060-00002
Le Reun E, Granzotto A, Pêtre A, Bodgi L, Beldjoudi G, Lacornerie T, et al. Influence of the hypersensitivity to low dose phenomenon on the tumor response to hypofractionated stereotactic body radiation therapy. Cancers (Basel). 2023;15(15):3979.
pubmed: 37568795
doi: 10.3390/cancers15153979
Bodgi L, Al-Choboq J, Araji T, Bou-Gharios J, Azzi J, Challita R, et al. Radiation treatment timing and dose delivery: effects on bladder cancer cells in 3D in vitro culture. Radiation. 2022;2(4):318–37.
doi: 10.3390/radiation2040025
George N, Joshi MB, Satyamoorthy K. DNA damage-induced senescence is associated with metabolomic reprogramming in breast cancer cells. Biochimie. 2023;216:71–82.
pubmed: 37758157
doi: 10.1016/j.biochi.2023.09.021
Pinar B, Henríquez-Hernández LA, Lara PC, Bordon E, Rodriguez-Gallego C, Lloret M, et al. Radiation induced apoptosis and initial DNA damage are inversely related in locally advanced breast cancer patients. Radiat Oncol. 2010;5:1–5.
doi: 10.1186/1748-717X-5-85